{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:03:04Z","timestamp":1772600584613,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["U01NS056975"],"award-info":[{"award-number":["U01NS056975"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["U01NS059041"],"award-info":[{"award-number":["U01NS059041"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["U01NS088023"],"award-info":[{"award-number":["U01NS088023"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["U01NS088034"],"award-info":[{"award-number":["U01NS088034"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annemergmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Emergency Medicine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.annemergmed.2022.04.020","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T04:43:21Z","timestamp":1655441001000},"page":"194-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4060-4445","authenticated-orcid":false,"given":"Zlatan","family":"Coralic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaideep","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kent R.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Overbeek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Silbergleit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annemergmed.2022.04.020_bib1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12245-008-0024-4","article-title":"Seizure visits in US emergency departments: epidemiology and potential disparities in care","volume":"1","author":"Pallin","year":"2008","journal-title":"Int J Emerg Med"},{"key":"10.1016\/j.annemergmed.2022.04.020_bib2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(15)00042-3","article-title":"Status epilepticus in adults","volume":"14","author":"Betjemann","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.annemergmed.2022.04.020_bib3","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","article-title":"Randomized trial of three anticonvulsant medications for status epilepticus","volume":"381","author":"Kapur","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2022.04.020_bib4","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A\u00a0definition and classification of status epilepticus\u2014report of the ILAE task force on classification of status epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.annemergmed.2022.04.020_bib5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.annemergmed.2022.04.020_bib6","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamaneurol.2017.4382","article-title":"Association of time to treatment with short-term outcomes for pediatric patients with refractory convulsive status epilepticus","volume":"75","author":"Ga\u00ednza-Lein","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.annemergmed.2022.04.020_bib7","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3201\/eid0806.010377","article-title":"Neurocysticercosis in radiographically imaged seizure patients in U.S. emergency departments","volume":"8","author":"Ong","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.annemergmed.2022.04.020_bib8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bcp.12720","article-title":"Treatment of drug-induced seizures","volume":"81","author":"Chen","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.annemergmed.2022.04.020_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12028-012-9695-z","article-title":"Guidelines for the evaluation and management of status epilepticus","volume":"17","author":"Brophy","year":"2012","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.annemergmed.2022.04.020_bib10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/15563650.2021.1894332","article-title":"A\u00a0systematic review of second line therapies in toxic seizures","volume":"59","author":"Fletcher","year":"2021","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.annemergmed.2022.04.020_bib11","series-title":"Goldfrank\u2019s Toxicologic Emergencies","author":"Nelson","year":"2019"},{"key":"10.1016\/j.annemergmed.2022.04.020_bib12","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0140-6736(20)30611-5","article-title":"Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial","volume":"395","author":"Chamberlain","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.annemergmed.2022.04.020_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/15563650.2017.1355056","article-title":"Levetiracetam in toxic seizures","volume":"56","author":"Lee","year":"2018","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.annemergmed.2022.04.020_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fneur.2014.00011","article-title":"Mechanisms of levetiracetam in the control of status epilepticus and epilepsy","volume":"5","author":"Deshpande","year":"2014","journal-title":"Front Neurol"},{"key":"10.1016\/j.annemergmed.2022.04.020_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40263-015-0240-4","article-title":"Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders","volume":"29","author":"Hammond","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.annemergmed.2022.04.020_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1528-1157.1994.tb02908.x","article-title":"Determinants of mortality in status epilepticus","volume":"35","author":"Towne","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.annemergmed.2022.04.020_bib17","first-page":"157","article-title":"Cocaine-associated seizures and incidence of status epilepticus","volume":"11","author":"Majlesi","year":"2010","journal-title":"West J Emerg Med"}],"container-title":["Annals of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064422002694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064422002694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T04:47:28Z","timestamp":1759294048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196064422002694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0196064422002694"],"URL":"https:\/\/doi.org\/10.1016\/j.annemergmed.2022.04.020","relation":{},"ISSN":["0196-0644"],"issn-type":[{"value":"0196-0644","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annemergmed.2022.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American College of Emergency Physicians.","name":"copyright","label":"Copyright"}]}}